Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207905 | 0.83 | PIK3CG (0.44) | LMNACYP1A2MAPTTHRBALOX15 | |
| SCHEMBL938963 | 0.75 | NPC1 (0.42) | CYP1A2MAPTSMN1; SMN2CASP3SENP7 | |
| SCHEMBL207265 | 0.75 | AHR (0.37) | CYP1A2MAPTALOX15MAPK1KMT2A | |
| SCHEMBL7375589 | 0.75 | ENPP2 (0.42) | LMNAMAPTALOX15KMT2AMEN1 | |
| SCHEMBL4152683 | 0.75 | RAB9A (0.42) | LMNACYP1A2MAPTKMT2AMEN1 | |
| SCHEMBL5331382 | 0.74 | AHR (0.36) | MAPTKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL940594 | 0.72 | ALDH1A1 (0.44) | LMNAMAPTTHRBKMT2AMEN1 | |
| SCHEMBL7193461 | 0.71 | ALDH1A1 (0.42) | LMNAMAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL11784689 | 0.71 | RAB9A (0.42) | CYP1A2MAPTALOX15KMT2AMEN1 | |
| SCHEMBL6411255 | 0.71 | NPC1 (0.36) | LMNAMAPTALOX15KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 362 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | claimed |
| WO-2021216812-A1 | GALACTOKINASE INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2021-10-28 | — | — | WO | claimed |
| US-20210147435-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2021-05-20 | — | — | US | claimed |
| EP-3321262-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2021-01-13 | — | — | EP | claimed |
| EP-3665156-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2020-06-17 | — | — | EP | claimed |
| WO-2019032743-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2019-02-14 | — | — | WO | claimed |
| EP-3321262-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2018-05-16 | — | — | EP | claimed |
| US-20180127393-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-05-10 | — | — | US | claimed |
| EP-2389066-B1 | CYCLOPENTADIONE DERIVED HERBICIDES | SYNGENTA LTD (GB) | 2017-07-05 | — | — | EP | claimed |
| EP-2387569-B1 | HERBCIDES | SYNGENTA LTD (GB) | 2016-06-15 | — | — | EP | claimed |
| EP-1254897-A1 | TRICYCLIC COMPOUNDS | Ube Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | claimed |
| US-20020151235-A1 | Dyed and/or printed nonwoven fabric | FIRMA CARL FREUDENBERG (DE) | 2002-10-17 | — | — | US | claimed |
| EP-1209281-A2 | Dyed or printed nonwoven | Carl Freudenberg KG (DE) | 2002-05-29 | — | — | EP | claimed |
| WO-2002023784-A2 | CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-03-21 | — | — | WO | claimed |
| US-6207404-B1 | SUBJECTING THE CYTOCHROME P450 ENZYME AND THE COUMARIN BASED COMPOUND TO CONDITIONS WHEREBY THE CYTOCHROME P450 ENZYME CATALYZES THE CONVERSION OF THE COUMARIN BASED COMPOUND TO A FLUORESCENT PRODUCT | GENTEST CORPORATION | 2001-03-27 | — | — | US | claimed |
| EP-0690104-A2 | Dye preparation | BASF Aktiengesellschaft (DE) | 1996-01-03 | — | — | EP | claimed |
| US-5310888-A | Calcium detection | MILES INC. (US) | 1994-05-10 | — | — | US | claimed |
| EP-0343894-B1 | BENZAMIDE PROTEASE INHIBITORS | PFIZER INC. (US) | 1992-06-10 | — | — | EP | claimed |
| US-4948891-A | ANTI-PLASMIN AND ANTI-THROMBIN AGENTS | PFIZER INC. (US) | 1990-08-14 | — | — | US | claimed |
| EP-0343894-A1 | Benzamide protease inhibitors | PFIZER INC. (US) | 1989-11-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | GALK1, GCK, GCKR | LMNA 1846/4885CYP1A2 3681/4885MAPT 2129/4885 |
| US-20180127393-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K11, TTBK1 | LMNA 1963/4885CYP1A2 4352/4885MAPT 395/4885 |
| US-20210147435-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | EIF4EBP1, EIF4B, EIF4E | LMNA 2497/4885CYP1A2 3307/4885MAPT 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.